The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Treatment Tips for Pulmonary Arterial Hypertension & ILD

Treatment Tips for Pulmonary Arterial Hypertension & ILD

July 19, 2018 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
LuckyStep / shutterstock.com

LuckyStep / shutterstock.com

CHICAGO—About 30 years ago, pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) began to outpace renal crisis as the main causes of death in scleroderma (SSc). But treating these lung complications has proved vexing for clinicians.

You Might Also Like
  • Low Blood Pressure Increases Risk of Death in Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
  • Listen to the Lungs: An Interview with Dr. Aryeh Fischer on ILD
  • From the Expert: New Advances in Treatment of Systemic Scleroderma
Explore This Issue
July 2018
Also By This Author
  • Data for Better Patient Care: As the RISE Registry Expands, So Do Its Ambitions

There is no easy way to predict who will develop PAH. There is no telltale antibody and no clear pattern of SSc symptoms that presage the condition, so screening is important, said Janet Pope, MD, MPH, chair of rheumatology at St. Joseph’s Health Care in London, Ontario, Canada.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“There’s a chance of us preventing worsening and helping the patients [with] this lethal complication—we can prolong survival,” Dr. Pope said. “We can’t predict who will develop PAH, and it is common in scleroderma, occurring in approximately 15% of patients. That’s why we screen.”

PAH Treatment

Older age of onset, long-standing SSc, severe ILD, a drop in diffusing capacity (DLCO) and possibly elevated uric acid (although this remains anecdotal) are associated with increased PAH, according to Dr. Pope. “The bottom line: It’s like [rheumatoid arthritis]. Use multiple drugs, start treatment earlier, prevent worsening by front-end loading and use different combinations of drugs,” she said. Treatment includes supportive care such as exercise, endothelin receptor agonists, phosphodiesterase type 5 (PDE5) inhibitors, prostacylins and the soluble guanylate cyclase, riociguat.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Pope cautioned that PDE5 inhibitors and riociguat are contraindicated as a combination, but combinations of the other strategies are acceptable, and bring the best results.

“That is really the trend,” she said. “And that’s a very expensive thing. But we do prevent clinical worsening and we’ve improved survival.” She noted that the survival rate for PAH in scleroderma has doubled twice during her time in practice.

ILD Treatment

As for ILD, pulmonologists sometimes say screening isn’t worth it because therapies don’t usually bring enough benefit. But there are differences of opinion, Dr. Pope said. “You can ask three people and get two answers, and the third answer is someone on the fence.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

In a survey study of practice patterns in which she participated, scleroderma experts said ILD deemed clinically relevant is mostly treated initially with mycophenolate mofetil, with cyclophosphamide as the most common second-line treatment. Then they move on to rituximab or agents undergoing testing in clinical trials, Dr. Pope said.1

“But they’re also saying that usually they don’t even try corticosteroids,” she said. “If patients are corticosteroid responsive, that’s a good prognosis, but it’s highly unlikely.” Those who do try prednisone tend to start with 1 mg/kg for a month, and they rapidly stop if there is no response, but if there is improvement in cough or dyspnea, they often use a maintenance dose of 10 mg/day or so.

When the time does come to treat, there is some guidance.

Based on her reading of the literature and her own clinical impression, a worse prognosis in ILD is seen when extensive disease appears on high-resolution CT, when fibrosis is present, with hypoxia or cough, when severe restriction appears on pulmonary function tests and, of course, when PAH is present as well.

Pages: 1 2 | Single Page

Filed Under: Conditions, Scleroderma Tagged With: 2018 State of the Art Clinical Symposium, cyclophosphamide, ILD, Interstitial Lung Disease, mycophenolate mofetil, nintedanib, PAH, pomalidomide and perfenidone, pulmonary arterial hypertension, rituximab, SSc, tocilizumabIssue: July 2018

You Might Also Like:
  • Low Blood Pressure Increases Risk of Death in Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
  • Listen to the Lungs: An Interview with Dr. Aryeh Fischer on ILD
  • From the Expert: New Advances in Treatment of Systemic Scleroderma
  • Diagnosing & Managing Pulmonary & Kidney Manifestations in Lupus

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)